

## Anti-Tim-3 [2C12] Bulk size M Ab01057-1.32-BS

This antibody has a D265A mutation affecting Fc receptor engagement.

This chimeric mouse antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Mouse IgG1-D265A, Fc Silenced, Kappa

**Clone Number:** 2C12

**Alternative Name(s) of Target:** CD366; HAVcr-2; HAVCR2; Hepatitis A virus cellular receptor 2 homolog; T-cell immunoglobulin and mucin domain containing 3; T-cell immunoglobulin and mucin domain-containing protein 3; T-cell immunoglobulin mucin receptor 3; T-cell membrane protein 3; TIM-3; TIMD-3; TIM3; 8B.2C12

**UniProt Accession Number of Target Protein:** Q8VIM0

**Published Application(s):** Blocking, therapeutic, FC, IF, IHC

**Published Species Reactivity:** Mouse

**Immunogen:** This antibody was raised by immunising rats with TIM-3:Ig fusion protein emulsified in complete Freund's adjuvant.

**Specificity:** This antibody is specific for murine TIM-3, a Th1-specific cell surface protein. TIM-3 is a type I transmembrane protein and contains an immunoglobulin and a mucin-like domain in its extracellular portion and a tyrosine phosphorylation motif in its cytoplasmic portion. This antibody binds to the BALB/c allele of TIM-3 while reactivity to the C57Bl/6 allele is significantly weaker.

**Application Notes:** This antibody was used in FACS, immunohistochemistry, immunofluorescence and a murine experimental autoimmune encephalomyelitis model to study the effects of TIM-3 triggering in dendritic cells (Anderson et al., 2007; PMID: 18006747). Furthermore, this antibody has been used in multiple FACS analyses for diverse immuno-oncological applications, such as to delineate how TIM-3 signaling on cells of the innate immune system critically influences regulation of the adaptive immune response (Frisancho-Kiss et al., 2006), to demonstrate the reversal of T cell exhaustion and restoration of anti-tumor immunity upon co-targeting Tim-3 and PD-1 pathways (Sakuishi et al., 2010; PMID: 20819927), and to examine the therapeutic potential of dendritic cell based vaccines against malignant glioma (Dey et al., 2015). This antibody has also been used in immunohistochemistry to aid the elucidation of the effects of Th2 immune deviation on corneal allograft survival and possible mechanisms of graft rejection (Beauregard et al., 2005). In addition, employing this anti-TIM-3 antibody as part of the combination immunotherapy (anti-TIM3 + anti-PD-1 +/- anti-CTLA-4) has been shown to be effective against experimental and carcinogen-

induced tumors in mice (Sakuishi et al., 2010; PMID: 20819927) (Ngiow et al., 2011; PMID: 21430066).

**Antibody First Published in:** Monney et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002 Jan 31;415(6871):536-41. doi: 10.1038/415536a. [PMID:11823861](#)

**Note on publication:** The original publication explores the role of Tim-3 in regulating macrophage activation and influencing the severity of Th1-dependent autoimmune diseases.

## Product Form

**Size:** 1 mg Purified antibody in bulk size.

**Purification:** Protein A affinity purified

**Supplied In:** PBS only.

**Storage Recommendation:** Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

**Concentration:** See vial label

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.